New Models to Tackle Rising Drug Costs in Medicare
Federal health officials are rolling out two innovative payment models designed to bridge the increasing gap between U.S. drug prices and those in other developed countries. This initiative comes as Medicare spending experiences a continual upward trend.
The GUARD Model Explained
The first strategy, named the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, focuses on medications under Medicare Part D. This five-year model aims to remedy the significant price disparities seen with certain medications, especially those where U.S. prices notably surpass those abroad.
Impact on Out-of-Pocket Costs
With GUARD, pharmaceutical manufacturers would need to offer rebates whenever U.S. drug prices exceed international benchmarks. This approach is intended to alleviate patients' out-of-pocket expenses while ensuring the quality of care remains intact.
Understanding the GLOBE Model
The second model, known as the Global Benchmark for Efficient Drug Pricing (GLOBE), is designed similarly but targets specific drugs under Medicare Part B. These are generally the medications administered in healthcare settings, which means the implications of this model stretch further into various chronic health treatments.
Launch Timeline and Key Features
GLOBE is set to commence on October 1, 2026, and continue through 2031, including a period of reconciliation into 2033. Like GUARD, GLOBE also mandates manufacturer rebates when U.S. prices exceed those in comparable nations.
Rising Prescription Drug Costs and Justification for Change
The Centers for Medicare & Medicaid Services (CMS) cites the dramatic increase in Medicare Part D drug spending as a driving force behind these proposals. For instance, gross spending soared from $121 billion in 2014 to a staggering $276 billion in just under a decade, reflecting an annual growth rate of nearly 10%. Today, Part D constitutes around 30% of the total drug expenditure in the United States.
Connection to Patient Health Outcomes
The implications of escalating drug prices are dire. Many older adults resort to skipping doses or altering their medication routines due to financial constraints, leading to adverse health outcomes which can escalate to increased hospital admissions—a concern CMS aims to mitigate through the GUARD initiative.
Manufacturer Reporting and Transparency
As part of both models' frameworks, manufacturers will report international pricing data to set benchmarks accurately. Moreover, the funds generated from rebates will flow into the Medicare Supplementary Medical Insurance Trust Fund, ensuring a sustainable approach to Medicare drug pricing.
Future Directives for Public Feedback
A public comment period for the Notice of Proposed Rulemaking is scheduled until February 23, 2026. This window allows stakeholders to voice their perspectives on these transformative proposals.
Frequently Asked Questions
What are the GUARD and GLOBE models?
These are new payment models introduced by federal health officials to reduce Medicare drug costs by implementing manufacturer rebates when U.S. prices exceed international benchmarks.
When will the GUARD and GLOBE models take effect?
The GUARD model starts on January 1, 2027, while the GLOBE model is set to commence on October 1, 2026.
Why are these models needed?
There is a significant discrepancy between U.S. drug prices and prices in other countries, often causing financial burdens for Medicare beneficiaries that can lead to serious health consequences.
How will the public be involved?
A public comment period is open until February 23, 2026, allowing individuals and organizations to provide input on the proposed models.
What will happen to the rebate funds?
Funds from manufacturer rebates will be directed into the Medicare Supplementary Medical Insurance Trust Fund, helping to sustain the overall Medicare system.
